Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.10) by 50 percent. This is a 66.67 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $44.135 million which missed the analyst consensus estimate of $44.328 million by 0.44 percent. This is a 6.46 percent increase over sales of $41.457 million the same period last year.